Checkpoint Inhibitors in Advanced/Metastatic Lung Cancer
Symposium
Symposium

Checkpoint Inhibitors in Advanced/Metastatic Lung Cancer

Evaluating Current and Emerging Strategies

Not a member of My prIME? Join now for instant access.

Meeting Overview

We are pleased to invite you to our satellite symposium, Evaluating Current and Emerging Strategies Using Checkpoint Inhibitors in the Fight Against Advanced/Metastatic Lung Cancer, to be held in conjunction with the European Society for Medical Oncology (ESMO).

This satellite symposium has been designed to provide participants with up-to-date information and practical considerations on how to best utilize immunotherapy in the management of non-small cell lung cancer (NSCLC) to improve patients’ outcomes.

Date and Location

Saturday, 9 September 2017
13.00 – 14.30

Pamplona Auditorium, Hall 4
IFEMA – Feria de Madrid
Madrid, Spain

Date/Time

Date/Time

Saturday, 9 September 2017
13.00 – 14.30

Location

Location

Madrid, Spain

CME

CME

1.5 AMA PRA Category 1 Credits

13.00 Welcome and introduction
David Planchard, MD, PhD
13.05 Test your knowledge of immunotherapy: What do you know about checkpoint inhibition in lung cancer?
David Planchard, MD, PhD
13.10 Current uses of checkpoint inhibitor therapy in the treatment of NSCLC
Enriqueta Felip, MD, PhD
13.20 Biomarkers in clinical practice: Benefits and limitations
Marina Garassino, MD
13.30 Incorporating checkpoint inhibitors into the management of NSCLC: An interactive exercise
David Planchard, MD, PhD, and Faculty Panel
13.40 Early identification and optimal management of immune-related adverse events (irAEs)
Jürgen R. Fischer, MD
13.50 Managing the irAEs seen with checkpoint inhibitor therapy: An interactive exercise
David Planchard, MD, PhD, and Faculty Panel
14.00 Safety and efficacy of emerging checkpoint inhibitors in NSCLC
Naiyer Rizvi, MD
14.15 Assessing what you have learned from this activity: Have you increased your knowledge base?
David Planchard, MD, PhD
14.25 prIME Points™ and Q & A
David Planchard, MD, PhD
14.30 Adjourn

    CHAIR

  • David Planchard, MD, PhDGustave Roussy
    Villejuif, France
  • FACULTY

  • Enriqueta Felip, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Jürgen R. Fischer, MDKlinik Löwenstein gGmbH
    Löwenstein, Germany
  • Marina Garassino, MDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Naiyer Rizvi, MDNew York-Presbyterian Hospital
    Columbia University Medical Center
    New York, New York, United States

This educational activity is specifically designed to meet the needs of medical oncologists, pulmonologists, and other multidisciplinary specialists involved in the treatment of patients with NSCLC.

After successful completion of this educational activity, participants should be able to:

  • Assess recent data on the efficacy/safety of checkpoint inhibitor therapy for the treatment of NSCLC
  • Implement appropriate treatments for NSCLC that incorporate the use of checkpoint inhibitors
  • Analyze recent efficacy and safety data on emerging checkpoint inhibitors, alone and in combination with other agents, in the treatment of NSCLC
  • Describe the benefits and limitations of using PD-L1 as a biomarker to guide treatment selection when managing NSCLC
  • Develop management strategies to address irAEs related to the use of checkpoint inhibitors

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME

Provider

This activity is provided by prIME Oncology.

SUNSHINE ACT AND EFPIA DISCLOSURE CODE

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.